<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347835">
  <stage>Registered</stage>
  <submitdate>15/12/2011</submitdate>
  <approvaldate>15/12/2011</approvaldate>
  <actrnumber>ACTRN12611001283965</actrnumber>
  <trial_identification>
    <studytitle>Use of serial 18F-fluorodeoxyglucose (FDG) and 18F-fluorothymidine (FLT) positron emission tomography (PET) &amp; computed tomography (CT) for candidates with non-small cell lung cancer (NSCLC)receiving radical chemo-radiation therapy</studytitle>
    <scientifictitle>A prospective study to investigate the impact of serial FDG and FLT PET scans on the radiation therapy treatment of patients with NSCLC</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>lung cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>FDG and FLT PET/CT scans at baseline, during week two and week four of therapy. 
Each scan involves the injection of a radiotracer (FDG or FLT).
Each scan is approximately 30 minutes in duration. 
Patients will be recruited over a five year period.</interventions>
    <comparator>Observational single arm study, standard treatment adminstered.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To simulate the administration of biologically adapted radiation therapy (BART) to patients with NSCLC using information gained from interim FLT &amp; FDG PET/CT scans.</outcome>
      <timepoint>Following recruitment of all patients</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the role of interim FLT &amp; FDG PET/CT scans as biomarkers of patient prognosis.</outcome>
      <timepoint>Overall survival (OS): time from first RT treatment until death from any cause.
Progression free survival (PFS): time from first RT until progression (local, regional &amp; distant).
OS and PFS will be assessed clinically and with diagnostic imaging, including a follow-up FDG PET/CT scan.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Written informed consent provided.
Histologically or cytologically confirmed NSCLC.
Candidate for radical RT (60Gy) &amp; concomitant chemotherapy (standard regimen determined by medical oncologist). 
Stage I - III disease (TNM 7th edition).
ECOG performance status 0-1.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Received previous thoracic RT or a complete macroscopic excision of tumour.
Pregnancy (Women of child-bearing age to ensure adequate contraceptive measures).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>23/10/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Peter MacCallum Cancer Centre</primarysponsorname>
    <primarysponsoraddress>St Andrews Place
East Melbourne
VIC 3001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress>GPO Box 1421
Canberra
ACT
2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Victorian Cancer Agency</fundingname>
      <fundingaddress>12 Victoria Street
Carlton
Melbourne
VIC 3053</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Melbourne</sponsorname>
      <sponsoraddress>Grattan Street
Parkville
Melbourne
VIC 3010</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Monash University</othercollaboratorname>
      <othercollaboratoraddress>Dept Medical Imaging and Radiation Sciences
Wellington Road
Clayton, 
VIC 3800</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to prospectively explore the anatomical and biological characteristics of non-small cell lung cancers (NSCLC) in patients receiving combined radiation therapy (RT)-chemotherapy treatment with a curative intent. Patients will undergo PET/CT scans during the course of their treatment using two different PET tracers. The first tracer, 18F-FDG, is a proven tracer in current clinical use used to detect glucose metabolism. The second, 18F-FLT, is a novel tracer that can visualize cellular division rates in tumour compared to normal tissue.</summary>
    <trialwebsite />
    <publication>Everitt S, Hicks R, Hicks R, Ball D, Kron T, Schneider-Kolsky M, Binns D, Walter T, Mac Manus M, Imaging cellular proliferation during chemo-radiotherapy: A pilot study of serial 18F-FLT-PET/CT imaging for non-small cell lung cancer, International Journal of Radiation Oncology Biology Physics, 2009, 75(4) pp1098-1104 (IF 4.290)
Everitt S J, Hicks RJ, Kron T, Schneider-Kolsky M, Binns D, Walter T, Ball D, Mac Manus M, Imaging Cellular Proliferation During Therapy: A Pilot Study of Serial 18F-FLT-PET Scanning During Chemoradiation for Non-small Cell Lung Cancer Journal of Thoracic Oncology, 2008, 3(11) Supp 4, A121 (IF 1.429)
Everitt S, A prospective study investigating the impact of serial PET/CT scans on the radiation therapy treatment of patients with lung cancer, Victorian Cancer Agency Conference, Melbourne August 2010, (Invited speaker)
Everitt S, J Callahan, T Kron, R Hicks, D Ball, M Schneider-Kolsky and M MacManus, Biologically guided radiation therapy: quality assurance and resource implications in longitudinal PET/CT studies; ESTRO/EANM: Molecular Imaging and Radiation Oncology; Brussels; Belgium March 2010
Everitt S, Hicks R, Ball D, Kron T, Schneider-Kolsky M, Binns D, Walter T, Mac Manus M, Serial 18F-FLT-PET/CT scanning to monitor cellular proliferation in NSCLC during chemoRT, European Association of Nuclear Medicine, Spain, October 2009
Everitt S, Hicks R, Ball D, Kron T, Schneider-Kolsky M, Binns D, Walter T, Mac Manus M, Monitoring cellular proliferation during chemo-radiotherapy: A pilot study of serial 18F-FLTPET/CT scanning for Non-Small Cell Lung Cancer, Royal Australian and New Zealand College of Radiologists and Faculty of Radiation Oncology/Australian Institute of Radiography/Australasian College of Physical Scientists and Engineers in Medicine Combined Scientific Meeting, Brisbane, Australia, October 2009
Everitt S, Hicks R, Ball D, Kron T, Schneider-Kolsky M, Binns D, Walter T, Mac Manus M, Monitoring cellular proliferation during chemo-radiotherapy: A pilot study of serial 18F-FLT-PET/CT scanning for Non-Small Cell Lung Cancer, 39th ASM Australia New Zealand Society of Nuclear Medicine, Sydney, March 2009</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>St Andrews Place
East Melbourne
VIC 3001</ethicaddress>
      <ethicapprovaldate>14/10/2008</ethicapprovaldate>
      <hrec>08/40</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash University</ethicname>
      <ethicaddress>Wellington Road
Clayton
VIC
3800</ethicaddress>
      <ethicapprovaldate>23/10/2008</ethicapprovaldate>
      <hrec>2008001483</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sarah Everitt</name>
      <address>Radiation Therapy
Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
VIC 8006</address>
      <phone>61 3 96561111</phone>
      <fax />
      <email>sarah.everitt@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Everitt</name>
      <address>Radiation Therapy
Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
VIC 8006</address>
      <phone>61 3 96561111</phone>
      <fax />
      <email>sarah.everitt@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Everitt</name>
      <address>Radiation Therapy
Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
VIC 8006</address>
      <phone>61 3 96561111</phone>
      <fax />
      <email>sarah.everitt@petermac.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>